Ng C G, Wong S K, Loh H S, Yee A
Department of Psychological Medicine University Malaya, Kuala Lumpur, Malaysia.
Department of Paediatric University Malaya, Kuala Lumpur, Malaysia;
Clin Ter. 2014;165(6):e384-90. doi: 10.7417/CT.2014.1778.
Escitalopram has widely been recognized as one of the most frequently used antidepressants, with superior tolerability and great efficacy in preventing major depressive disorder (MDD) relapse and recurrence. However, anhedonia, which is a core symptom of MDD, remains difficult to treat. This study investigates the hedonic levels of MDD patients treated with Escitalopram.
A total of 108 participants, 26 of whom with MDD on Escitalopram, were recruited in this cross sectional study. They were evaluated using the Snaith-Hamilton Pleasure Scale (SHAPS) and Beck Depression Inventory (BDI) questionnaires to assess their hedonic state, general mental health condition and level of depression.
Our study shows that most items in the SHAPS scores are significantly different between MDD patients on Escitalopram and the controls.
The hedonic capacity remains different between the two groups despite patients with MDD are put on Escitalopram treatment. Escitalopram fails to alleviate the hedonic state of MDD patients. Antidepressants that improve both depressive symptoms and hedonic states should be considered when treating MDD patients in clinical settings.
艾司西酞普兰已被广泛认为是最常用的抗抑郁药之一，在预防重度抑郁症（MDD）复发方面具有卓越的耐受性和显著疗效。然而，快感缺失作为MDD的核心症状，仍然难以治疗。本研究调查了接受艾司西酞普兰治疗的MDD患者的享乐水平。
在这项横断面研究中，共招募了108名参与者，其中26名正在服用艾司西酞普兰的MDD患者。使用斯奈斯 - 汉密尔顿愉悦量表（SHAPS）和贝克抑郁量表（BDI）问卷对他们进行评估，以评估他们的享乐状态、总体心理健康状况和抑郁程度。
我们的研究表明，服用艾司西酞普兰的MDD患者与对照组之间，SHAPS评分中的大多数项目存在显著差异。
尽管MDD患者接受了艾司西酞普兰治疗，但两组之间的享乐能力仍然存在差异。艾司西酞普兰未能缓解MDD患者的享乐状态。在临床治疗MDD患者时，应考虑使用既能改善抑郁症状又能改善享乐状态的抗抑郁药。
